Glofitamab Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

Total Trials

Recruiting

Completed

7,749

Total Enrollment

States

Glofitamab Clinical Trials

Sortable list of all 74 Glofitamab trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

Glofitamab History and Updates

Every FDA approval, label revision, recall, trial milestone, and pivotal publication for Glofitamab — sourced from openFDA, ClinicalTrials.gov, and PubMed.

See full history →

Recent Glofitamab updates

See full history →

Columvi Label Receives Boxed Warning for Cytokine Release Syndrome· Jun 3, 2026

What Is Glofitamab?

Glofitamab is a medication that has been approved for marketing in China for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). It is a cytolytic monoclonal antibody, meaning it is an antibody designed to target and kill specific cells. Glofitamab works by targeting the CD19 protein found on the surface of certain cancer cells, particularly B-cells involved in lymphomas. By binding to CD19, it helps the immune system identify and destroy these cancerous cells.

Globally, Glofitamab is currently being investigated in clinical trials for various types of lymphoma. As of the latest data, there are 74 trials involving Glofitamab, with 39 trials actively recruiting new participants. These studies have enrolled a total of 7,749 participants, with the earliest trial starting on March 9, 2017, and the latest projected to conclude on April 14, 2026.

Uses and Conditions Under Study

Glofitamab is being studied for its potential to treat several types of lymphomas, which are cancers that begin in infection-fighting cells of the immune system called lymphocytes. The drug's mechanism of targeting CD19-expressing B-cells makes it relevant for a range of B-cell lymphomas.

Diffuse Large B-cell Lymphoma (DLBCL) and Related Conditions: This aggressive form of non-Hodgkin lymphoma is a primary focus for Glofitamab. It is being investigated for relapsed/refractory DLBCL, high-risk DLBCL, and high-grade B-cell lymphoma. Glofitamab's ability to target CD19 on these cancer cells is crucial for its potential efficacy. These conditions are being studied in a combined total of 22 trials.
Mantle Cell Lymphoma (MCL): This is a rare and often aggressive type of non-Hodgkin lymphoma. Glofitamab is being explored for its use in patients with MCL, including those who have previously received CAR T-cell therapy. The drug's action against CD19-positive cells is also relevant here. Mantle Cell Lymphoma is the subject of 11 trials.
Other B-cell Lymphomas: Glofitamab is also under investigation for other B-cell lymphomas, including general lymphoma and B-cell lymphoma. These studies aim to understand the drug's broader applicability across different forms of lymphatic cancer. A total of 10 trials are looking into these broader categories.
Specific Lymphoma Subtypes: Clinical trials are also evaluating Glofitamab for more specific and less common lymphoma subtypes. These include Richter's Transformation, which is a rare complication of chronic lymphocytic leukemia, as well as follicular lymphoma and marginal zone lymphoma. These investigations aim to determine if Glofitamab can offer therapeutic benefits in these distinct patient populations. For example, one study (NCT05421717) is evaluating Glofitamab for untreated follicular lymphoma or marginal zone lymphoma.

Dosing

Glofitamab is administered as an intravenous infusion, with specific dosing regimens being studied in clinical trials. A common approach involves a "step-up" dosing strategy to help manage potential side effects. For example, one regimen starts with a dose of 2.5 mg on Cycle 1 Day 1, followed by 10 mg on Cycle 1 Day 8. This is then typically followed by a maintenance dose of 30 mg administered every 3 weeks for a total of 3 cycles.

For patients who achieve a partial response (PR) or better after these initial cycles, further treatment may include autologous stem cell transplant (ASCT) followed by an additional 3 cycles of post-consolidation Glofitamab at 30 mg every 3 weeks. Glofitamab is being studied both as a monotherapy and in various combination therapies. These combinations include other agents like polatuzumab vedotin, R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone), obinutuzumab, pirtobrutinib, and CAR T-cell therapy, among others, to explore enhanced efficacy for conditions such as relapsed/refractory Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Side Effects

In a study (NCT04313608) involving patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade large B-cell lymphoma, the safety of Glofitamab in combination with gemcitabine and oxaliplatin (GemOx) was compared to mosunetuzumab with GemOx. The study did not include a placebo group. The most common side effects reported were:

Serious adverse events occurred in 70.6% of patients receiving Glofitamab with GemOx, compared to 66.7% of patients receiving mosunetuzumab with GemOx.
Cytokine Release Syndrome (CRS) was reported in 47.1% of patients on the Glofitamab combination, with 11.8% experiencing severe (Grade 3) CRS. In comparison, 16.7% of patients on the mosunetuzumab combination experienced CRS, with no severe cases reported.
Dose interruptions due to side effects occurred in 29.4% of patients on the Glofitamab combination, compared to 50.0% of patients on the mosunetuzumab combination.
Dose reductions due to side effects were reported in 5.9% of patients on the Glofitamab combination, compared to 16.7% of patients on the mosunetuzumab combination.
Treatment discontinuations due to adverse events occurred in 1 patient in the Glofitamab group and 1 patient in the mosunetuzumab group.
One death due to an adverse event occurred in the Glofitamab group, while no deaths due to adverse events occurred in the mosunetuzumab group.

Clinical Trial Results

In a clinical study (NCT04313608) evaluating patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade large B-cell lymphoma, the effectiveness of Glofitamab in combination with gemcitabine and oxaliplatin (GemOx) was compared to mosunetuzumab with GemOx.

The complete response rate, which signifies the disappearance of all signs of cancer based on PET/CT scans, was 23.5% for patients treated with Glofitamab plus GemOx. In comparison, 50.0% of patients treated with mosunetuzumab plus GemOx achieved a complete response.

The objective response rate (ORR), which includes both complete and partial responses to treatment, was 35.3% for the Glofitamab combination. For the mosunetuzumab combination, the ORR was 50.0%.

Currently Recruiting Trials

Researchers are actively recruiting participants for clinical trials investigating glofitamab across various B-cell lymphomas. These studies aim to understand the drug's safety and effectiveness, often in combination with other therapies, for patients whose disease has returned or not responded to previous treatments. One ongoing Phase 2 trial, NCT07003295, is testing glofitamab alongside obinutuzumab in patients with mantle cell lymphoma (MCL) that has relapsed or is refractory after CAR-T cell therapy. This study, sponsored by the National Cancer Institute (NCI), aims to enroll 20 participants. Another Phase 2 study, NCT07257055, sponsored by M.D. Anderson Cancer Center, is exploring glofitamab consolidation after BTKi-rituximab induction for 30 patients with high-risk untreated MCL. For patients with relapsed or refractory large B-cell lymphoma (LBCL) with specific genetic changes (TP53 aberrations), a Phase 2 study (NCT07240194) is evaluating glofitamab in combination with a PD-1 inhibitor and lenalidomide, targeting 24 participants. Central nervous system (CNS) lymphoma is the focus of a Phase 1 trial (NCT06922604) at City of Hope Medical Center, which is assessing glofitamab with obinutuzumab in 20 patients. Hoffmann-La Roche is sponsoring a Phase 1 study (NCT06624085) in the U.S. to evaluate glofitamab combined with gemcitabine and oxaliplatin for 50 participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A larger Phase 3 trial, NCT06084936, is comparing glofitamab monotherapy against an investigator's choice of treatment for 182 patients with relapsed or refractory MCL. Additionally, a Phase 1/2 study (NCT05533775) is investigating glofitamab for 65 pediatric and young adult participants with relapsed or refractory mature B-cell non-Hodgkin lymphoma.

Where to Participate

Clinical trials for glofitamab are widely accessible, with studies currently active across 156 sites in 95 cities and 39 states. This broad reach ensures that many patients may have the opportunity to participate. The top cities with the most recruiting sites include:

New York, New York (13 sites)
Boston, Massachusetts (9 sites)
Atlanta, Georgia (7 sites)
Houston, Texas (6 sites)
Duarte, California (6 sites)
Salt Lake City, Utah (4 sites)
Philadelphia, Pennsylvania (4 sites)
Nashville, Tennessee (4 sites)
Portland, Oregon (4 sites)
Miami, Florida (4 sites)

Eligibility for these trials generally includes individuals aged 6 to 80 years, of all genders. Healthy volunteers are not eligible to participate, but children are included in some studies.

Development Timeline

The journey of glofitamab began with its first clinical trial on March 9, 2017. Initially, early explorations included conditions such as IBS-C and hyperphosphatemia, before the development path significantly broadened to focus on B-cell malignancies. Hoffmann-La Roche has been a primary driver of glofitamab's development, sponsoring 17 of the 74 total trials conducted to date. Over time, the pipeline expanded to address a wide range of B-cell lymphomas, including Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), and various forms of Non-Hodgkin Lymphoma. The drug's development has progressed through multiple phases, with 40 trials reaching Phase 2, 14 in Phase 1, and 10 as Phase 1/Phase 2 studies. Three trials are currently in Phase 3, representing advanced stages of investigation. These studies have collectively enrolled 7,749 participants, with the latest trial projected to conclude on April 14, 2026. This extensive research aims to bring new treatment options to patients facing challenging lymphomas.

Glofitamab Development Timeline

Clinical trial activity from 2017 to 2026.

2026

NCT07444710PHASE1not yet recruiting

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

NCT07003295PHASE2recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

NCT07528352PHASE1recruiting

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

12 enrolled

NCT07502872PHASE2not yet recruiting

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

30 enrolled

NCT07387848PHASE2not yet recruiting

Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas

40 enrolled

NCT07453095PHASE2not yet recruiting

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

41 enrolled

NCT07257055PHASE2recruiting

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

30 enrolled

NCT07514169PHASE2recruiting

The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL

30 enrolled

NCT07326371PHASE2not yet recruiting

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

24 enrolled

NCT07231250PHASE2not yet recruiting

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

40 enrolled

NCT07480850PHASE2active not recruiting

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

40 enrolled

2025

NCT06994169recruiting

Glofitamab in Real Life

250 enrolled

NCT07184788PHASE2not yet recruiting

G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma

80 enrolled

NCT07200375recruiting

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

300 enrolled

NCT06665217PHASE2not yet recruiting

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

80 enrolled

NCT07240194PHASE2recruiting

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

24 enrolled

NCT07460362PHASE2recruiting

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

43 enrolled

NCT06922604PHASE1recruiting

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

20 enrolled

NCT06670105PHASE2withdrawn

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

0 enrolled

NCT07012980PHASE2not yet recruiting

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

38 enrolled

NCT06956092PHASE4not yet recruiting

Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

40 enrolled

NCT06357676PHASE1/PHASE2recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

27 enrolled

NCT06570447PHASE2recruiting

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

22 enrolled

NCT06996132PHASE2recruiting

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

25 enrolled

NCT06624085PHASE1recruiting

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

50 enrolled

NCT06867536PHASE2recruiting

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

40 enrolled

NCT06806033PHASE2recruiting

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

NCT06558604PHASE2recruiting

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

100 enrolled

NCT06050694PHASE2recruiting

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

40 enrolled

NCT06765317PHASE2recruiting

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

42 enrolled

2024

NCT06534437PHASE2recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

178 enrolled

NCT06054776PHASE2recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

40 enrolled

NCT06656221PHASE2not yet recruiting

A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

29 enrolled

NCT06634589PHASE1/PHASE2recruiting

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

NCT06552572PHASE2active not recruiting

Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy

30 enrolled

NCT06656234not yet recruiting

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

200 enrolled

NCT06651853PHASE2recruiting

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

22 enrolled

NCT06567366PHASE2not yet recruiting

CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors

45 enrolled

NCT06393738PHASE1recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

255 enrolled

NCT06071871PHASE2recruiting

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

99 enrolled

NCT06252675PHASE2recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

30 enrolled

NCT06497452recruiting

A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

50 enrolled

NCT06213311PHASE2recruiting

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

40 enrolled

NCT06186648PHASE2recruiting

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

40 enrolled

NCT06043674PHASE2recruiting

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

70 enrolled

NCT06192888PHASE1active not recruiting

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

39 enrolled

NCT06481826recruiting

Glofitamab in Chinese Patients With R/R DLBCL

20 enrolled

2023

NCT06090539PHASE1/PHASE2recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

308 enrolled

NCT06084936PHASE3recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

182 enrolled

NCT05833763PHASE2recruiting

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

42 enrolled

NCT06047080PHASE3active not recruiting

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

1,130 enrolled

NCT05896163PHASE1/PHASE2terminated

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

40 enrolled

NCT05861050PHASE1/PHASE2recruiting

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

50 enrolled

NCT05783596PHASE2active not recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

47 enrolled

NCT05800366PHASE2recruiting

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

NCT05798156PHASE2active not recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

125 enrolled

2022

NCT05533775PHASE1/PHASE2recruiting

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

65 enrolled

NCT05364424PHASE1completed

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

43 enrolled

NCT05169515PHASE1recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

121 enrolled

NCT04970901PHASE1recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

200 enrolled

NCT05335018PHASE2active not recruiting

GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

76 enrolled

NCT04980222PHASE2active not recruiting

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

46 enrolled

NCT05219513PHASE1terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

53 enrolled

2021

NCT04889716PHASE2recruiting

CAR-T Followed by Bispecific Antibodies

23 enrolled

NCT04914741PHASE1/PHASE2active not recruiting

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

80 enrolled

NCT04408638PHASE3active not recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

270 enrolled

NCT04657302PHASE1completed

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

30 enrolled

2020

NCT04231877PHASE1recruiting

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

NCT04161248EARLY_PHASE1active not recruiting

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

40 enrolled

NCT04313608PHASE1completed

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

23 enrolled

2019

NCT04077723PHASE1/PHASE2active not recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

498 enrolled

2018

NCT03533283PHASE1/PHASE2active not recruiting

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

211 enrolled

NCT03467373PHASE1completed

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

111 enrolled

2017

NCT03075696PHASE1/PHASE2active not recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

940 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Mantle Cell Lymphoma	NCT07453095	Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy	not yet recruiting	PHASE2	41
	NCT06357676	Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial	recruiting	PHASE1/PHASE2	27
	NCT06054776	Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	recruiting	PHASE2	40
	NCT06656221	A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma	not yet recruiting	PHASE2	29
	NCT06252675	Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma	recruiting	PHASE2	30
	NCT06192888	A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma	active not recruiting	PHASE1	39
	NCT05833763	A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.	recruiting	PHASE2	42
	NCT05861050	Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma	recruiting	PHASE1/PHASE2	50
Lymphoma	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30
	NCT06624085	A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	recruiting	PHASE1	50
	NCT06867536	Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden	recruiting	PHASE2	40
	NCT06084936	A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma	recruiting	PHASE3	182
	NCT05800366	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma	recruiting	PHASE2	41
	NCT04980222	A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	46
	NCT04657302	A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	completed	PHASE1	30
Large B-cell Lymphoma	NCT06994169	Glofitamab in Real Life	recruiting	N/A	250
	NCT07240194	The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study	recruiting	PHASE2	24
	NCT06567366	CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors	not yet recruiting	PHASE2	45
	NCT06071871	A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma	recruiting	PHASE2	99
	NCT06047080	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma	active not recruiting	PHASE3	1,130
	NCT04889716	CAR-T Followed by Bispecific Antibodies	recruiting	PHASE2	23
DLBCL - Diffuse Large B Cell Lymphoma	NCT07326371	Glofitamab Combined With CAR-T Therapy in R/R DLBCL	not yet recruiting	PHASE2	24
	NCT07231250	Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma	not yet recruiting	PHASE2	40
	NCT06481826	Glofitamab in Chinese Patients With R/R DLBCL	recruiting	N/A	20
	NCT04889716	CAR-T Followed by Bispecific Antibodies	recruiting	PHASE2	23
Diffuse Large B Cell Lymphoma	NCT07528352	External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL	recruiting	PHASE1	12
	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30
	NCT06552572	Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy	active not recruiting	PHASE2	30
	NCT04914741	A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)	active not recruiting	PHASE1/PHASE2	80
Diffuse Large B-Cell Lymphoma	NCT07200375	An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma	recruiting	N/A	300
	NCT06665217	G-Pola-ZLP in Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	80
	NCT07012980	Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL	not yet recruiting	PHASE2	38
	NCT06651853	Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL	recruiting	PHASE2	22
	NCT05896163	A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.	terminated	PHASE1/PHASE2	40
	NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE3	270
MCL	NCT07257055	Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study	recruiting	PHASE2	30
	NCT07460362	Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma	recruiting	PHASE2	43
	NCT06192888	A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma	active not recruiting	PHASE1	39
B-cell Lymphoma	NCT06670105	A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma	withdrawn	PHASE2	0
	NCT06634589	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies	recruiting	PHASE1/PHASE2	80
	NCT04313608	A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma	completed	PHASE1	23
	NCT03467373	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	completed	PHASE1	111
Diffuse Large B Cell Lymphoma (DLBCL)	NCT06050694	Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)	recruiting	PHASE2	40
	NCT06765317	A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma	recruiting	PHASE2	42
	NCT06656234	The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study	not yet recruiting	N/A	200
High-grade B-cell Lymphoma	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30
	NCT04914741	A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)	active not recruiting	PHASE1/PHASE2	80
Lymphoma, Non-Hodgkin	NCT05219513	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	terminated	PHASE1	53
	NCT04077723	A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	active not recruiting	PHASE1/PHASE2	498
Lymphoma, Large B-Cell, Diffuse	NCT05800366	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma	recruiting	PHASE2	41
	NCT05798156	Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP	active not recruiting	PHASE2	125
Diffuse Large B-cell Lymphoma	NCT07200375	An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma	recruiting	N/A	300
	NCT06665217	G-Pola-ZLP in Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	80
	NCT07012980	Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL	not yet recruiting	PHASE2	38
	NCT06651853	Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL	recruiting	PHASE2	22
	NCT05896163	A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.	terminated	PHASE1/PHASE2	40
	NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE3	270
Lymphoma, B-Cell	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30
	NCT04161248	Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma	active not recruiting	EARLY_PHASE1	40
Non-Hodgkin Lymphoma	NCT05169515	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma	recruiting	PHASE1	121
	NCT03467373	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	completed	PHASE1	111
BTKi	NCT07257055	Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study	recruiting	PHASE2	30
Chemo-free Therapy	NCT07231250	Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma	not yet recruiting	PHASE2	40
Chronic Lymphocytic Leukemia	NCT06043674	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation	recruiting	PHASE2	70
Diffuse Large B-Cell Lymphoma-Recurrent	NCT06570447	Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL	recruiting	PHASE2	22
Diffuse Large B-Cell Lymphoma-Refractory	NCT06570447	Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL	recruiting	PHASE2	22
Diffuse Large B-Cell Lymphoma (DLBCL)	NCT05364424	A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma	completed	PHASE1	43
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Diffuse Large B Cell Lymphoma Refractory	NCT07387848	Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas	not yet recruiting	PHASE2	40
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Follicular Lymphoma	NCT05783596	Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma	active not recruiting	PHASE2	47
Glofitamab	NCT07257055	Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study	recruiting	PHASE2	30
Gray-Zone Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
High Grade B-Cell Lymphoma, Not Otherwise Specified	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
High Grade B Cell Lymphoma	NCT06765317	A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma	recruiting	PHASE2	42
Indolent Non-hodgkin Lymphoma	NCT05783596	Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma	active not recruiting	PHASE2	47
Large B-Cell Lymphoma	NCT06994169	Glofitamab in Real Life	recruiting	N/A	250
	NCT07240194	The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study	recruiting	PHASE2	24
	NCT06567366	CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors	not yet recruiting	PHASE2	45
	NCT06071871	A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma	recruiting	PHASE2	99
	NCT06047080	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma	active not recruiting	PHASE3	1,130
	NCT04889716	CAR-T Followed by Bispecific Antibodies	recruiting	PHASE2	23
Large B-Cell Lymphoma (LBCL)	NCT07514169	The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL	recruiting	PHASE2	30
Lymphoma, Mantle-Cell	NCT06558604	Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma	recruiting	PHASE2	100
Mantle Cell Lymphoma Refractory	NCT05833763	A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.	recruiting	PHASE2	42
Marginal Zone Lymphoma	NCT05783596	Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma	active not recruiting	PHASE2	47
Mature B-Cell Non-Hodgkin Lymphoma	NCT05533775	A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	65
Non-Hodgkin's Lymphoma	NCT03075696	A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma	active not recruiting	PHASE1/PHASE2	940
Non-Hodgkin Lymphoma, B-cell	NCT06534437	MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)	recruiting	PHASE2	178
Non-Hodgkins Lymphoma	NCT03533283	An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	active not recruiting	PHASE1/PHASE2	211
Phase 2 Study	NCT07257055	Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study	recruiting	PHASE2	30
Pleomorphic Variant Mantle Cell Lymphoma	NCT05861050	Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma	recruiting	PHASE1/PHASE2	50
Primary Central Nervous System Lymphoma	NCT06922604	Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma	recruiting	PHASE1	20
Primary Mediastinal Large B-Cell Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Recurrent Mantle Cell Lymphoma	NCT07003295	Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy	recruiting	PHASE2	20
Refractory B-Cell Non-Hodgkin Lymphoma	NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200
Refractory Cancer	NCT06634589	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies	recruiting	PHASE1/PHASE2	80
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	NCT07480850	Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	40
Refractory Mantle Cell Lymphoma	NCT07003295	Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy	recruiting	PHASE2	20
Relapsed and Refractory	NCT06651853	Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL	recruiting	PHASE2	22
Relapsed B-Cell Non-Hodgkin Lymphoma	NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200
Relapsed Cancer	NCT06634589	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies	recruiting	PHASE1/PHASE2	80
Relapsed or Refractory Aggressive B-cell Lymphoma	NCT06996132	Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma	recruiting	PHASE2	25
Relapsed or Refractory Mantle Cell Lymphoma (MCL)	NCT07460362	Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma	recruiting	PHASE2	43
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)	NCT06393738	A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.	recruiting	PHASE1	255
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)	NCT06393738	A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.	recruiting	PHASE1	255
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	NCT06867536	Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden	recruiting	PHASE2	40
Relapsed/refractory Diffuse Large B Cell Lymphoma	NCT05335018	GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma	active not recruiting	PHASE2	76
Relapsed/Refractory Non-Hodgkin Lymphoma	NCT06090539	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas	recruiting	PHASE1/PHASE2	308
Richter's Transformation	NCT06043674	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation	recruiting	PHASE2	70
Richter Syndrome	NCT06186648	Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome	recruiting	PHASE2	40
Rituximab	NCT07257055	Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study	recruiting	PHASE2	30
Secondary Central Nervous System Lymphoma	NCT06922604	Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma	recruiting	PHASE1	20
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Aggressive B-Cell Lymphoma	NCT07184788	G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma	not yet recruiting	PHASE2	80
TP53	NCT07240194	The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study	recruiting	PHASE2	24
Aggressive Non-Hodgkin Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
ALK-Positive Large B-Cell Lymphoma	NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56
Ann Arbor Stage II Mantle Cell Lymphoma	NCT07444710	Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma	not yet recruiting	PHASE1	16
Ann Arbor Stage III Mantle Cell Lymphoma	NCT07444710	Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma	not yet recruiting	PHASE1	16
Ann Arbor Stage IV Mantle Cell Lymphoma	NCT07444710	Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma	not yet recruiting	PHASE1	16
B-Cell Lymphoma	NCT06670105	A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma	withdrawn	PHASE2	0
	NCT06634589	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies	recruiting	PHASE1/PHASE2	80
	NCT04313608	A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma	completed	PHASE1	23
	NCT03467373	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	completed	PHASE1	111
B-cell Malignancy	NCT06634589	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies	recruiting	PHASE1/PHASE2	80
B-cell Non-Hodgkin Lymphoma	NCT06497452	A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.	recruiting	N/A	50
	NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200
B-Cell Non-Hodgkin Lymphoma	NCT06497452	A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.	recruiting	N/A	50
	NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200
B-Cell Non-Hodgkins Lymphoma	NCT06806033	A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	recruiting	PHASE2	100
B Cell Lymphoma	NCT06213311	A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma	recruiting	PHASE2	40
B Cell Lymphoma (BCL)	NCT06956092	Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma	not yet recruiting	PHASE4	40
Bispecific Antibody	NCT07231250	Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma	not yet recruiting	PHASE2	40
Blastoid Variant Mantle Cell Lymphoma	NCT05861050	Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma	recruiting	PHASE1/PHASE2	50

All Glofitamab Clinical Trials (74)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT07444710	Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma	not yet recruiting	PHASE1	16	National Cancer Institute (NCI)
NCT07003295	Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy	recruiting	PHASE2	20	National Cancer Institute (NCI)
NCT07528352	External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL	recruiting	PHASE1	12	University of Utah
NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	not yet recruiting	PHASE2	30	Brown University
NCT07387848	Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas	not yet recruiting	PHASE2	40	American University of Beirut Medical Center
NCT07453095	Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy	not yet recruiting	PHASE2	41	Fondazione Italiana Linfomi - ETS
NCT07257055	Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study	recruiting	PHASE2	30	M.D. Anderson Cancer Center
NCT07514169	The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL	recruiting	PHASE2	30	Ruijin Hospital
NCT07326371	Glofitamab Combined With CAR-T Therapy in R/R DLBCL	not yet recruiting	PHASE2	24	Ruijin Hospital
NCT07231250	Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma	not yet recruiting	PHASE2	40	Li Zhiming
NCT07480850	Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	40	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06994169	Glofitamab in Real Life	recruiting	N/A	250	The Lymphoma Academic Research Organisation
NCT07184788	G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma	not yet recruiting	PHASE2	80	Navy General Hospital, Beijing
NCT07200375	An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma	recruiting	N/A	300	Hoffmann-La Roche
NCT06665217	G-Pola-ZLP in Diffuse Large B-Cell Lymphoma	not yet recruiting	PHASE2	80	Navy General Hospital, Beijing
NCT07240194	The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study	recruiting	PHASE2	24	The First Affiliated Hospital with Nanjing Medical University
NCT07460362	Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma	recruiting	PHASE2	43	Peking University Third Hospital
NCT06922604	Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma	recruiting	PHASE1	20	City of Hope Medical Center
NCT06670105	A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma	withdrawn	PHASE2	0	M.D. Anderson Cancer Center
NCT07012980	Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL	not yet recruiting	PHASE2	38	Shanghai Zhongshan Hospital
NCT06956092	Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma	not yet recruiting	PHASE4	40	Zhengzhou University
NCT06357676	Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial	recruiting	PHASE1/PHASE2	27	OHSU Knight Cancer Institute
NCT06570447	Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL	recruiting	PHASE2	22	Tianjin Medical University Cancer Institute and Hospital
NCT06996132	Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma	recruiting	PHASE2	25	Institute of Hematology & Blood Diseases Hospital, China
NCT06624085	A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	recruiting	PHASE1	50	Hoffmann-La Roche
NCT06867536	Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden	recruiting	PHASE2	40	Liling Zhang
NCT06806033	A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	recruiting	PHASE2	100	Hoffmann-La Roche
NCT06558604	Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma	recruiting	PHASE2	100	The Lymphoma Academic Research Organisation
NCT06050694	Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)	recruiting	PHASE2	40	University Health Network, Toronto
NCT06765317	A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma	recruiting	PHASE2	42	Memorial Sloan Kettering Cancer Center
NCT06534437	MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)	recruiting	PHASE2	178	Ryvu Therapeutics SA
NCT06054776	Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	recruiting	PHASE2	40	City of Hope Medical Center
NCT06656221	A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma	not yet recruiting	PHASE2	29	Ruijin Hospital
NCT06634589	A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies	recruiting	PHASE1/PHASE2	80	BeOne Medicines
NCT06552572	Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy	active not recruiting	PHASE2	30	Samsung Medical Center
NCT06656234	The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study	not yet recruiting	N/A	200	Ruijin Hospital
NCT06651853	Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL	recruiting	PHASE2	22	The First Affiliated Hospital of Xiamen University
NCT06567366	CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors	not yet recruiting	PHASE2	45	Ruijin Hospital
NCT06393738	A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.	recruiting	PHASE1	255	Arvinas Inc.
NCT06071871	A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma	recruiting	PHASE2	99	University College, London
NCT06252675	Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma	recruiting	PHASE2	30	University of California, San Francisco
NCT06497452	A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.	recruiting	N/A	50	The First Affiliated Hospital of Soochow University
NCT06213311	A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma	recruiting	PHASE2	40	M.D. Anderson Cancer Center
NCT06186648	Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome	recruiting	PHASE2	40	French Innovative Leukemia Organisation
NCT06043674	Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation	recruiting	PHASE2	70	Christine Ryan
NCT06192888	A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma	active not recruiting	PHASE1	39	Memorial Sloan Kettering Cancer Center
NCT06481826	Glofitamab in Chinese Patients With R/R DLBCL	recruiting	N/A	20	Peking Union Medical College Hospital
NCT06090539	A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas	recruiting	PHASE1/PHASE2	308	Bristol-Myers Squibb
NCT06084936	A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma	recruiting	PHASE3	182	Hoffmann-La Roche
NCT05833763	A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.	recruiting	PHASE2	42	Australasian Leukaemia and Lymphoma Group
NCT06047080	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma	active not recruiting	PHASE3	1,130	Hoffmann-La Roche
NCT05896163	A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.	terminated	PHASE1/PHASE2	40	Pfizer
NCT05861050	Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma	recruiting	PHASE1/PHASE2	50	City of Hope Medical Center
NCT05783596	Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma	active not recruiting	PHASE2	47	Reid Merryman, MD
NCT05800366	A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma	recruiting	PHASE2	41	Jennifer Crombie, MD
NCT05798156	Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP	active not recruiting	PHASE2	125	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT05533775	A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma	recruiting	PHASE1/PHASE2	65	Hoffmann-La Roche
NCT05364424	A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma	completed	PHASE1	43	Hoffmann-La Roche
NCT05169515	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma	recruiting	PHASE1	121	Hoffmann-La Roche
NCT04970901	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	recruiting	PHASE1	200	ADC Therapeutics S.A.
NCT05335018	GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma	active not recruiting	PHASE2	76	Seoul National University Hospital
NCT04980222	A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE2	46	Hoffmann-La Roche
NCT05219513	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	terminated	PHASE1	53	Hoffmann-La Roche
NCT04889716	CAR-T Followed by Bispecific Antibodies	recruiting	PHASE2	23	Abramson Cancer Center at Penn Medicine
NCT04914741	A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)	active not recruiting	PHASE1/PHASE2	80	Peter MacCallum Cancer Centre, Australia
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	PHASE3	270	Hoffmann-La Roche
NCT04657302	A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	completed	PHASE1	30	Hoffmann-La Roche
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma	recruiting	PHASE1	56	University of Washington
NCT04161248	Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma	active not recruiting	EARLY_PHASE1	40	Canadian Cancer Trials Group
NCT04313608	A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma	completed	PHASE1	23	Hoffmann-La Roche
NCT04077723	A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	active not recruiting	PHASE1/PHASE2	498	Hoffmann-La Roche
NCT03533283	An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	active not recruiting	PHASE1/PHASE2	211	Hoffmann-La Roche
NCT03467373	A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL	completed	PHASE1	111	Hoffmann-La Roche
NCT03075696	A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma	active not recruiting	PHASE1/PHASE2	940	Hoffmann-La Roche

Where to Participate: All Glofitamab Trial Sites in the U.S. (169 sites across 37 states)

Every actively recruiting Glofitamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Children's Hospital of Alabama	Birmingham35233	NCT05533775	Map
AK	Alaska Oncology & Hematology, LLC	Anchorage99508	NCT06806033	Map
AZ	Mayo Clinic in Arizona - Phoenix	Phoenix85054	NCT06090539	Map
AZ	Mayo Clinic Phoenix	Phoenix85054-4502	NCT06634589	Map
CA	Community Cancer Institute (CCI)	Clovis93611	NCT06806033	Map
CA	University of California San Francisco - Fresno Center for Medical Education and Research	Clovis93611	NCT04970901	Map
CA	University of California, Davis	Davis95616	NCT06252675	Map
CA	City of Hope Cancer Center	Duarte91010	NCT06084936	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06090539	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT07003295	Map
CA	City of Hope Medical Center	Duarte91010	NCT05861050	Map
CA	City of Hope Medical Center	Duarte91010	NCT06054776	Map
CA	City of Hope Medical Center	Duarte91010	NCT06922604	Map
CA	Providence Medical Foundation	Fullerton92835	NCT06806033	Map
CA	Los Angeles Cancer Network	Glendale91204	NCT06806033	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT06624085	Map
CA	Saddleback Memorial Medical Center	Laguna Hills92653	NCT06624085	Map
CA	University of California, Los Angeles	Los Angeles90095	NCT06252675	Map
CA	University of Southern California Norris Comprehensive	Los Angeles90033	NCT06634589	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT06806033	Map
CA	Kaiser Permanente Oakland Medical Center	Oakland94611	NCT05533775	Map
CA	UCSF Benioff Children's Hospital Oakland	Oakland94609	NCT05533775	Map
CA	Valkyrie Clinical Trials	Panorama City91402	NCT06806033	Map
CA	Kaiser Permanente - Roseville	Roseville95661	NCT05533775	Map
CA	Scripps Health - Prebys Cancer Center	San Diego92103	NCT04970901	Map
CA	UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program	San Francisco94143	NCT05169515	Map
CA	University of California, San Francisco	San Francisco94143	NCT06252675	Map
CA	Zuckerberg San Francisco General Hospital	San Francisco94110	NCT06806033	Map
CA	Kaiser Permanente - Santa Clara	Santa Clara95051	NCT05533775	Map
CA	University of California Los Angeles (UCLA) - Cancer Care - Santa Monica	Santa Monica90404-2023	NCT06084936	Map
CA	University of California Los Angeles (UCLA) - Cancer Care - Santa Monica	Santa Monica90404-2023	NCT06624085	Map
CA	The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente	Torrance90502-2006	NCT06806033	Map
CO	Rocky Mountain Cancer Centers, LLP	Aurora80012	NCT06806033	Map
CO	University of Colorado	Aurora80045	NCT05169515	Map
CT	Clinical Trial Site	New Haven06510	NCT06393738	Map
CT	Yale Cancer Center	New Haven06520	NCT06084936	Map
DC	Georgetown University	Washington D.C.20007	NCT06084936	Map
DC	Georgetown University	Washington D.C.20007	NCT06624085	Map
FL	University of Miami	Coral Gables33146	NCT06084936	Map
FL	North Florida/ South Georgia VA Medical Center	Gainesville32608	NCT06806033	Map
FL	Mayo Clinic Jacksonville	Jacksonville32224-1865	NCT06634589	Map
FL	Miami Cancer Institute	Miami33176	NCT04970901	Map
FL	Mount Sinai Comprehensive Cancer Center	Miami33140	NCT06806033	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT04970901	Map
FL	University of Miami Sylvester Cancer Center	Miami33136	NCT05800366	Map
FL	AdventHealth Cancer Institute	Orlando32804	NCT06624085	Map
FL	Orlando Health Cancer Institute	Orlando32806	NCT06806033	Map
FL	Memorial Cancer Institute - Memorial Hospital West	Pembroke Pines33028	NCT04970901	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05169515	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06090539	Map
FL	Moffitt Cancer Center	Tampa33612-9496	NCT06634589	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT07003295	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT07003295	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT07003295	Map
GA	The Blood and Marrow Transplant Group of Georgia	Atlanta30342	NCT04970901	Map
GA	Winship Cancer Institute at Emory University	Atlanta30322	NCT06043674	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT04970901	Map
GA	Winship Cancer Institute of Emory University	Atlanta30329	NCT06624085	Map
ID	St Luke?s Cancer Institute	Boise83712	NCT06806033	Map
IL	The University of Chicago	Chicago60637	NCT05169515	Map
IL	University of Illinois Cancer Center	Chicago60612	NCT06624085	Map
IL	Cancer Care Specialists of Central Illinois	Swansea62226	NCT06806033	Map
IA	Mission Cancer + Blood - Mission Cancer Foundation	Des Moines50309	NCT04970901	Map
IA	Mission Blood and Cancer - MercyOne Cancer Center	Waukee50263	NCT06806033	Map
KS	Kansas City VA Medical Center	Kansas City64128	NCT06624085	Map
KS	The University of Kansas Cancer Center	Westwood66205-2003	NCT06634589	Map
KY	University of Kentucky - Markey Cancer Center	Lexington40536	NCT06806033	Map
LA	Mary Bird Perkins Cancer Ctr	Baton Rouge70809	NCT06806033	Map
MD	Johns Hopkins University	Baltimore21231	NCT05533775	Map
MD	Walter Reed National Military Medical Center	Bethesda20814	NCT06624085	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT04970901	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT05800366	Map
MA	Boston Medical Center	Boston02118	NCT06806033	Map
MA	Brigham and Women's Hospital	Boston02215	NCT06043674	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05800366	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06043674	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05533775	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT04970901	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06090539	Map
MI	University of Michigan Health System	Ann Arbor48109	NCT06084936	Map
MI	Clinical Trial Site	Detroit48201	NCT06393738	Map
MI	Corewell Health	Grand Rapids49503	NCT06806033	Map
MN	University of Minnesota	Minneapolis55455	NCT04970901	Map
MN	Mayo Clinic in Rochester, Minnesota	Rochester55905	NCT06090539	Map
MN	Mayo Clinic Rochester	Rochester55905-0001	NCT06634589	Map
MO	St. Luke's Hospital	Chesterfield63017	NCT06084936	Map
MO	Childrens Mercy Hosp & Clinics	Kansas City64108	NCT05533775	Map
MO	Washington University School of Medicine	St Louis63110-1010	NCT06634589	Map
NE	Nebraska Cancer Specialists	Omaha68130	NCT06806033	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT04889716	Map
NV	Renown Regional Medical Center	Reno89502	NCT06084936	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT06765317	Map
NJ	Summit Medical Group	Florham Park07932-1049	NCT06634589	Map
NJ	Hackensack Meridian Health (Data collection only)	Hackensack07601	NCT06765317	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT06765317	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT06765317	Map
NJ	Clinical Trial Site	New Brunswick10065	NCT06393738	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT06084936	Map
NM	Christus Health - Christus St. Vincent Regional Medical Center	Santa Fe87505	NCT06624085	Map
NY	New York Oncology Hematology, P.C.	Albany12206	NCT06806033	Map
NY	Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)	Commack11725	NCT06765317	Map
NY	Hematology Oncology Associates of Central New York	East Syracuse13057	NCT06806033	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT06765317	Map
NY	Clinical Trial Site	New York10016	NCT06393738	Map
NY	Clinical Trial Site	New York10021	NCT06393738	Map
NY	Columbia University Irving Medical Center	New York10027	NCT04970901	Map
NY	Columbia University Medical Center	New York10032	NCT06634589	Map
NY	Icahn School of Medicine At Mount Sinai	New York10029-6504	NCT06634589	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06090539	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT06765317	Map
NY	Memorial Sloan Kettering Cancer Center Mskcc	New York10065-6800	NCT06634589	Map
NY	MSKCC	New York10065	NCT05533775	Map
NY	Weill Cornell Medical College Newyork Presbyterian Hospital	New York10065-4870	NCT06634589	Map
NY	University of Rochester	Rochester14642	NCT06084936	Map
NY	University of Rochester	Rochester14642-0001	NCT06634589	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Rockville Centre11553	NCT06765317	Map
NY	Stony Brook Univ Cancer Ctr	Stony Brook11794	NCT06624085	Map
NC	The University of North Carolina at Chapel Hill	Chapel Hill27599	NCT06043674	Map
NC	Levine Cancer Institute	Charlotte28204	NCT05169515	Map
NC	East Carolina University	Greenville27834	NCT06624085	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT05533775	Map
OH	Cleveland Clinic Main Campus	Cleveland44195	NCT04970901	Map
OH	Clinical Trial Site	Cleveland44122	NCT06393738	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT07003295	Map
OH	The Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06043674	Map
OR	Oncology Associates of Oregon, P.C	Eugene97401	NCT06806033	Map
OR	OHSU Knight Cancer Institute	Portland97239	NCT06357676	Map
OR	Oregon Health and Science University	Portland97239	NCT04970901	Map
OR	Providence Portland Medical Center	Portland97213	NCT06806033	Map
OR	Providence St. Vincent Medical Center	Portland97225	NCT06806033	Map
PA	Abramson Cancer Center of the University of Pennsylvania	Philadelphia19104	NCT04889716	Map
PA	Fox Chase Cancer Center	Philadelphia19111-2434	NCT06634589	Map
PA	Penn Medicine - Perelman Center for Advanced Medicine	Philadelphia19104	NCT04970901	Map
PA	Thomas Jefferson University	Philadelphia19107	NCT06624085	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT07003295	Map
RI	Brown University Health - Rhode Island Hospital	Providence02903	NCT04970901	Map
TN	Tennessee Oncology	Chattanooga37403	NCT06806033	Map
TN	Clinical Trial Site	Nashville37203	NCT06393738	Map
TN	Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR)	Nashville37203	NCT04970901	Map
TN	Tennessee Oncology	Nashville37203	NCT06806033	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT07003295	Map
TX	Baylor University Medical Center	Dallas75246	NCT04970901	Map
TX	Renovatio Clinical - El Paso	El Paso79915	NCT06084936	Map
TX	Renovatio Clinical - El Paso	El Paso79915	NCT06624085	Map
TX	Baylor College of Medicine	Houston77030	NCT06624085	Map
TX	Clinical Trial Site	Houston77030	NCT06393738	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06213311	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07257055	Map
TX	The University of Texas Md Anderson Cancer Center	Houston77030-4009	NCT06634589	Map
TX	UT MD Anderson Cancer Center	Houston77030	NCT05169515	Map
TX	Baylor Scott & White Health	Temple76502	NCT06806033	Map
TX	Renovatio Clinical	The Woodlands77380	NCT06084936	Map
TX	Renovatio Clinical	The Woodlands77380	NCT06624085	Map
TX	Texas Oncology - Gulf Coast	The Woodlands77380	NCT06806033	Map
TX	Texas Oncology- Northeast Texas	Tyler75702	NCT06806033	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT04970901	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT05861050	Map
UT	Huntsman Cancer Institute	Salt Lake City84112-5550	NCT06634589	Map
UT	Huntsman Cancer Institute at University of Utah	Salt Lake City84112	NCT07528352	Map
VA	Emily Couric Clinical Cancer Center	Charlottesville22903	NCT04970901	Map
VA	University of Virginia	Charlottesville22906	NCT06084936	Map
VA	Virginia Cancer Specialists, PC	Fairfax22031	NCT06806033	Map
VA	Virginia Oncology Associates - Virginia Beach	Virginia Beach23456	NCT06806033	Map
WA	Fred Hutch/University of Washington Cancer Consortium	Seattle98109	NCT04231877	Map
WA	Northwest Medical Specialties	Tacoma98405	NCT06806033	Map
WV	West Virginia University	Morgantown26506	NCT06084936	Map
WI	University of Wisconsin	Madison53792-0001	NCT06634589	Map
WI	Froedtert & Medical College of Wisconsin	Milwaukee53226	NCT04970901	Map
WI	Medical College of Wisconsin	Milwaukee53226-1222	NCT06634589	Map

Browse Glofitamab Trials by State

New York clinical trials Massachusetts clinical trials Georgia clinical trials Texas clinical trials California clinical trials Utah clinical trials Pennsylvania clinical trials Tennessee clinical trials Oregon clinical trials Florida clinical trials

glofitamabmantle cell lymphomalymphomalarge b-cell lymphomadlbcl - diffuse large b cell lymphomadiffuse large b cell lymphomaclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated June 2, 2026.

Recent Glofitamab updates

What Is Glofitamab?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Glofitamab Development Timeline

Conditions Under Study

All Glofitamab Clinical Trials (74)

Sponsors

Where to Participate: All Glofitamab Trial Sites in the U.S. (169 sites across 37 states)

Browse Glofitamab Trials by State